ArticleLife science alliance2022
Analyzing efficacy, stability, and safety of AAV-mediated optogenetic hearing restoration in mice.
Article in Life science alliance, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 20 citations in OpenAlex.
- Immune response to adeno-associated viral vectors in a human iPSC-derived microglia chimeric mouse model.Cell reports methods · 2026Article
- Channelrhodopsin variants for high-rate optogenetic neurostimulation at low light intensities.EMBO molecular medicine · 2026Article
- Two Decades of Optogenetic Tools: A Retrospective and a Look Ahead.Advanced genetics (Hoboken, N.J.) · 2025Review
- Study on Recovery Strategy of Hearing Loss & SGN Regeneration Under Physical Regulation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Improved optogenetic modification of spiral ganglion neurons for future optical cochlear implants.Theranostics · 2025Article
- Optogenetics in oral and craniofacial research.Journal of Zhejiang University. Science. B · 2024Review
- Optogenetics and Targeted Gene Therapy for Retinal Diseases: Unravelling the Fundamentals, Applications, and Future Perspectives.Journal of clinical medicine · 2024Review
- Review
- Channelrhodopsin fluorescent tag replacement for clinical translation of optogenetic hearing restoration.Molecular therapy. Methods & clinical development · 2023Article
- AAV genome modification for efficient AAV production.Heliyon · 2023Review
- Patient perspectives on the need for improved hearing rehabilitation: A qualitative survey study of German cochlear implant users.Frontiers in neuroscience · 2023Article
- Is there an unmet medical need for improved hearing restoration?EMBO molecular medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
AAV-mediated optogenetic neural stimulation has become a clinical approach for restoring function in sensory disorders and feasibility for hearing restoration has been indicated in rodents. Nonetheless, long-term stability and safety of AAV-mediated channelrhodopsin (ChR) expression in spiral ganglion neurons (SGNs) remained to be addressed. Here, we used longitudinal studies on mice subjected to early postnatal administration of AAV2/6 carrying fast gating ChR f-Chrimson under the control of the human synapsin promoter unilaterally to the cochlea. f-Chrimson expression in SGNs in both ears and the brain was probed in animals aged 1 mo to 2 yr. f-Chrimson was observed in SGNs at all ages indicating longevity of ChR-expression. SGN numbers in the AAV-injected cochleae declined with age faster than in controls. Investigations were extended to the brain in which viral transduction was observed across the organ at varying degrees irrespective of age without observing viral spread-related pathologies. No viral DNA or virus-related histopathological findings in visceral organs were encountered. In summary, our study demonstrates life-long (24 mo in mice) expression of f-Chrimson in SGNs upon single AAV-dosing of the cochlea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.